ROSOPATAMAB TETRAXETAN LUTETIUM LU-177

UNII:	JB9647672Z
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	ROSOPATAMAB TETRAXETAN LUTETIUM LU-177
GSRS Full Record:	JB9647672Z i

2866236-96-4
177 LU-DOTA-ROSOPATAMAB
DOTA-HUJ-591 LU-177
H-gamma1 heavy chain (1-445) [VH Musmus/Homsap (Mus musculus IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%) T123>L (110)/Homo sapiens IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%) V124>L (111), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV6-23*01 (81.8%) -IGKJ2*03 (72.7%) S120>P (100), L124>V (104), E125>D (105)/Homo sapiens IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; conjugated via the side chain nitrogen of an average of 4 lysine residues to lutetium (177Lu) radiolabelled 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodecan-1-yl]acetyl (tetraxetan, DOTA)
HUJ591-GS (177LU-J591)
Immunoglobulin G1, anti-(human prostate-specific membrane antigen) (human-Mus musculus monoclonal Huj591 γ1-chain), disulfide with human-Mus musculus monoclonal Huj591 κ-chain, dimer, N6-[2-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κO]-L-lysine complex with lutetium-177Lu
LUTETIUM (177LU) J591
Lutetium (177Lu) J591 [WHO-DD]
Rosopatamab tetraxetan lutetium Lu-177
TLX-591
TLX591
immunoglobulin G1-kappa, anti-[Homo sapiens FOLH1(folate hydrolase, prostate specific membrane antigen, PSMA)], lutetium (177Lu) radiolabelled tetraxetan conjugate
lutetium (177Lu) rosopatamab tetraxetan
lutetium (177Lu) rosopatamab tetraxetan [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ROSOPATAMAB TETRAXETAN LUTETIUM LU-177

Synonyms and Mappings

Resources